Median Technologies to Present at TD Cowen’s 45th Annual Health Care Conference

Median Technologies to Present at TD Cowen’s 45th Annual Health Care Conference

MEDIAN TECHNOLOGIES
Emmanuelle Leygues
VP, Corporate Marketing & Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

U.S. media & investors
Chris Maggos
COHESION BUREAU
+41 79 367 6254
chris.maggos@cohesionbureau.com

Investors
Ghislaine Gasparetto
SEITOSEI ACTIFIN
+33 6 21 10 49 24
ghislaine.gasparetto@seitosei-actifin.com

Press
Caroline Carmagnol
ALIZE RP
+33 6 64 18 99 59
median@alizerp.com

Regulatory News:

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, announced today that it will participate in TD Cowen’s 45th Annual Health Care Conference, taking place March 3-5 in Boston, MA.

Fredrik Brag, Median’s CEO and Founder, will present on the Company, latest developments and upcoming milestones on Tuesday, March 4 at 3:10 pm ET (9:10 pm CET).

Investors, analysts, members of the media and the general public are invited to register and listen to a live webcast of the presentation at this weblink. A webcast replay will be available on Median Technologies’ website Investors section shortly after the presentation.

About Median Technologies: Pioneering innovative imaging solutions and Software as a Medical Device, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.